Market Tracker

09/29 5:16pm ET

Merck & Co Inc (NYSE:MRK)

61.91
Delayed Data
As of 4:00pm ET
 -1.39 / -2.20%
Today’s Change
47.97
Today|||52-Week Range
64.00
+17.21%
Year-to-Date
Deutsche Bank's Losses Affecting the Market on Thursday
6:05pm / GuruFocus News - Paid Partner Content
Takeover Chatter Around Clovis May Be Overdone
Sep 23 / TheStreet.com - Paid Partner Content
Stocks Higher With OPEC Agreement
10:16am / GuruFocus News - Paid Partner Content
BioLineRx Begins Trial on BL-8040/ Keytruda Combination
Sep 21 / Zacks.com - Paid Partner Content
Gilead Sciences Stock Downgraded: 3 Things You Need to Know
Sep 28 / MotleyFool.com - Paid Partner Content
Opinions split on Witty regime at GSK
Sep 20 / FT.com - Paid Partner Content
Investors Reward Merck Despite Flat Revenue Growth
Sep 27 / GuruFocus News - Paid Partner Content
Theresa May Assures IBM, Amazon, Goldman Sachs About Brexit
Sep 20 / Zacks.com - Paid Partner Content
Eli Lilly Stock Upgraded: What You Need to Know
Sep 27 / MotleyFool.com - Paid Partner Content
Meet Big Pharma's new female CEO
Sep 20 / CNNMoney.com
Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S.
Sep 27 / Zacks.com - Paid Partner Content
How Safe Is Gilead Sciences Inc. and Its Dividend?
Sep 20 / MotleyFool.com - Paid Partner Content
Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy
Sep 27 / TheStreet.com - Paid Partner Content
This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspect...
Sep 19 / MotleyFool.com - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
Sep 16 / Zacks.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
Europeans are among those most sceptical of vaccine safety
Sep 14 / FT.com - Paid Partner Content
Can You Guess Which Big Pharma Has Raised Its Drug Prices 5 Times Since June 2014?
Sep 26 / MotleyFool.com - Paid Partner Content
Bristol-Myers Squibb misses mark with cancer drug
Aug 30 / FT.com - Paid Partner Content